Treatment of post-transplant lymphoproliferative disease with rituximab monoclonal antibody after lung transplantation.

Cook, R C; Connors, J M; Gascoyne, R D; Fradet, G; Levy, R D · Lancet · 1999

case_series · Level IV

Where this comes from

Abstract

Three patients with diffuse large B-cell type of post-transplant lymphoproliferative disease after lung transplantation were treated with rituximab, an anti-CD20 monoclonal antibody. Treatment resulted in two complete remissions and one non-response.

Medical subject headings